Profile data is unavailable for this security.
About the company
Haleon plc is a consumer healthcare company. The Company's product portfolio includes five categories, including oral health, vitamins, minerals, and supplements (VMS), pain relief, respiratory health, digestive health and others. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA and LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company's digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.
- Revenue in USD (TTM)14.08bn
- Net income in USD1.31bn
- Incorporated2021
- Employees24.00k
- LocationHALEON PLCBuilding 5, First Floor, The HeightsBRENTFORD KT13 0NYUnited KingdomGBR
- Phone+44 193 282 2000
- Websitehttps://www.haleon.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICON PLC | 8.12bn | 612.34m | 25.53bn | 41.10k | 41.81 | 2.76 | 21.30 | 3.14 | 7.40 | 7.40 | 98.17 | 112.02 | 0.4752 | -- | 2.99 | 197,571.20 | 3.59 | 3.93 | 4.28 | 4.80 | 29.66 | 28.91 | 7.55 | 7.37 | -- | 3.15 | 0.2901 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
| Biogen Inc | 9.84bn | 1.16bn | 29.36bn | 7.57k | 25.32 | 1.98 | 17.73 | 2.99 | 7.98 | 7.98 | 67.67 | 102.14 | 0.3827 | 1.31 | 4.64 | 1,299,287.00 | 4.52 | 12.53 | 5.20 | 14.83 | 74.24 | 81.84 | 11.81 | 26.93 | 1.26 | 3.86 | 0.3192 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
| DuPont de Nemours Inc | 12.07bn | 494.00m | 30.92bn | 24.00k | 71.32 | 1.31 | 18.41 | 2.56 | 1.04 | 0.9256 | 26.77 | 56.45 | 0.302 | 3.50 | 4.94 | 502,833.30 | 1.33 | 0.3709 | 1.48 | 0.468 | 35.08 | 35.69 | 4.42 | 1.97 | 1.73 | 6.61 | 0.2398 | 414.03 | -7.29 | -11.79 | -51.19 | 11.24 | -30.66 | -20.59 |
| Gartner Inc | 5.91bn | 882.47m | 35.11bn | 20.24k | 40.76 | 51.91 | 32.70 | 5.94 | 11.07 | 11.07 | 74.13 | 8.69 | 0.7805 | -- | 3.68 | 291,888.90 | 11.66 | 8.24 | 22.74 | 14.76 | 67.78 | 67.55 | 14.94 | 12.20 | -- | 12.01 | 0.7832 | -- | 7.87 | 8.24 | 9.24 | 49.78 | -4.06 | -- |
| HALEON PLC - ADR | 14.08bn | 1.31bn | 37.47bn | 24.00k | 29.69 | -- | 48.97 | 2.66 | 0.2812 | 0.2812 | 3.03 | -- | 0.3282 | 3.15 | 5.76 | 586,812.10 | 3.23 | -- | 3.73 | -- | 61.59 | -- | 9.83 | -- | 0.7349 | 7.37 | 0.3611 | -- | 4.09 | -- | -1.04 | -- | -- | -- |
| Moderna Inc | 6.85bn | -4.71bn | 41.68bn | 5.60k | -- | 3.00 | -- | 6.09 | -12.39 | -12.39 | 17.68 | 36.27 | 0.3093 | 8.15 | 6.01 | 1,222,857.00 | -21.29 | 20.95 | -25.94 | 29.51 | 31.47 | -- | -68.84 | 32.10 | 3.36 | -- | 0.0399 | 0.00 | -64.45 | 119.28 | -156.37 | -- | 46.22 | -- |
| Iqvia Holdings Inc | 14.98bn | 1.36bn | 43.71bn | 87.00k | 33.00 | 7.15 | 17.60 | 2.92 | 7.30 | 7.30 | 80.42 | 33.67 | 0.5761 | -- | 4.76 | 172,229.90 | 5.22 | 3.24 | 6.80 | 4.07 | 34.96 | 34.32 | 9.06 | 6.03 | -- | 3.24 | 0.6911 | 0.00 | 3.98 | 7.55 | 24.47 | 43.39 | 7.17 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Dodge & Coxas of 31 Dec 2023 | 110.66m | 2.42% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 27.33m | 0.60% |
| Strategic Advisers LLCas of 31 Dec 2023 | 27.18m | 0.60% |
| ClearBridge Investments LLCas of 31 Dec 2023 | 26.58m | 0.58% |
| Harding Loevner LPas of 31 Dec 2023 | 22.37m | 0.49% |
| Fisher Asset Management LLCas of 31 Dec 2023 | 14.74m | 0.32% |
| Wellington Management Co. LLPas of 31 Dec 2023 | 13.54m | 0.30% |
| AllianceBernstein LPas of 31 Dec 2023 | 10.94m | 0.24% |
| FIAM LLCas of 31 Dec 2023 | 9.39m | 0.21% |
| Aristotle Capital Management LLCas of 31 Dec 2023 | 8.91m | 0.20% |
